European Journal of Haematology

Papers
(The H4-Index of European Journal of Haematology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect118
67
59
Issue Information57
Myeloproliferative Neoplasms and Dementia Risk: A Population‐Based Cohort Study55
Augmenter of liver regeneration promotes drug resistance of acute lymphoblastic leukemia through the alteration of mitochondrial functions and the inhibition of the mitochondrial apoptosis pathway54
The association of age and adverse events of PEG‐asparaginase in a pediatric tertiary care hospital; a retrospective review40
Comparison of Hetrombopag and Eltrombopag Added to First‐Line Immunosuppressive Therapy in Severe Aplastic Anemia36
Pixantrone as a bridge to CAR‐T treatment in high‐grade transformation of follicular lymphoma35
Application of thromboelastography to predict the severity of bleeding after chimeric antigen receptor (CAR)‐T cell therapy in patients with hematological malignancy32
Platelet transfusions and predictors of bleeding in patients with myelodysplastic syndromes31
Impact of Gut Microbiota and Inflammatory Cytokines on Immune Thrombocytopenia28
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma28
Utilization and outcome disparities in allogeneic hematopoietic stem cell transplant in the United States26
Salvage Therapies After Anti‐BCMA CAR‐T Failure in Patients With Multiple Myeloma: A Meta‐Analysis of Response Rates26
Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization26
Nationwide study of eculizumab in paroxysmal nocturnal hemoglobinuria: Evaluation of treatment indications and outcomes24
Prophylaxis with recombinant von Willebrand factor in patients with type 3 von Willebrand disease: Results of a post hoc analysis from a phase 3 trial24
Vaccination in Multiple Myeloma: Challenges and Strategies22
Plasma microbial cell‐free DNA following chimeric antigen receptor T cell therapy in pediatric patients with relapsed/refractory leukemia21
Desensitization protocol to lenalidomide: An effective and safe treatment modality for delayed hypersensitivity‐induced rash in patients with multiple myeloma20
Long‐term effectiveness of eculizumab: Data from the International PNH Registry20
0.13958621025085